ClearPoint Neuro 향후 성장

Future 기준 점검 2/6

ClearPoint Neuro 의 수익은 연간 2.7% 감소할 것으로 예상되는 반면, 연간 수익은 41.5% 로 증가할 것으로 예상됩니다. EPS는 연간 2.4% 만큼 성장할 것으로 예상됩니다.

핵심 정보

-2.7%

이익 성장률

2.36%

EPS 성장률

Medical Equipment 이익 성장	13.3%
매출 성장률	41.5%
향후 자기자본이익률	n/a
애널리스트 커버리지	Low
마지막 업데이트	26 Nov 2025

최근 향후 성장 업데이트

Recent updates

ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) 39% Cheaper Price Remains In Tune With Revenues

Nov 10

Is ClearPoint Neuro (NASDAQ:CLPT) A Risky Investment?

Nov 03

ClearPoint Neuro: AMT-130 Highlights A Bright Future

Oct 02

Why Investors Shouldn't Be Surprised By ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) 84% Share Price Surge

Sep 25

After Leaping 31% ClearPoint Neuro, Inc. (NASDAQ:CLPT) Shares Are Not Flying Under The Radar

May 04

ClearPoint Neuro: Fundamentals Continue To Strengthen

Apr 29

Cell And Gene Therapy Delivery Will Expand Global Partnerships

Mar 29 Strategic partnerships and global expansion aim to boost revenue and earnings through enhanced technology access and new pharma agreements.

After Leaping 25% ClearPoint Neuro, Inc. (NASDAQ:CLPT) Shares Are Not Flying Under The Radar

Feb 14

After Leaping 26% ClearPoint Neuro, Inc. (NASDAQ:CLPT) Shares Are Not Flying Under The Radar

Dec 10

Investors Appear Satisfied With ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Prospects As Shares Rocket 28%

Sep 14

Is ClearPoint Neuro (NASDAQ:CLPT) Weighed On By Its Debt Load?

Aug 16

Investors Appear Satisfied With ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Prospects As Shares Rocket 26%

Jul 11

ClearPoint Neuro, Inc. (NASDAQ:CLPT) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

May 09

ClearPoint Neuro: Macro-Induced Multiple Compression

Apr 25

Are ClearPoint Neuro, Inc. (NASDAQ:CLPT) Investors Paying Above The Intrinsic Value?

Apr 19

Analysts Have Made A Financial Statement On ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Yearly Report

Mar 15

Should You Investigate ClearPoint Neuro, Inc. (NASDAQ:CLPT) At US$6.18?

Jan 04

Does ClearPoint Neuro (NASDAQ:CLPT) Have A Healthy Balance Sheet?

Dec 06

Is There An Opportunity With ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) 41% Undervaluation?

Nov 06

이익 및 매출 성장 예측

NasdaqCM:CLPT - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)
날짜	매출	이익	자유현금흐름	영업현금흐름	평균 애널리스트 수
12/31/2026	56	-24	N/A	N/A	2
12/31/2025	37	-23	N/A	N/A	2
9/30/2025	34	-23	-14	-13	N/A
6/30/2025	34	-22	-12	-11	N/A
3/31/2025	32	-21	-12	-11	N/A
12/31/2024	31	-19	-9	-9	N/A
9/30/2024	30	-18	-9	-9	N/A
6/30/2024	28	-18	-10	-9	N/A
3/31/2024	26	-21	-13	-12	N/A
12/31/2023	24	-22	-15	-14	N/A
9/30/2023	22	-22	-17	-16	N/A
6/30/2023	22	-21	-19	-18	N/A
3/31/2023	21	-18	-19	-18	N/A
12/31/2022	21	-16	-17	-16	N/A
9/30/2022	20	-16	-18	-17	N/A
6/30/2022	19	-16	-17	-16	N/A
3/31/2022	17	-16	-15	-15	N/A
12/31/2021	16	-14	-13	-13	N/A
9/30/2021	16	-12	-12	-12	N/A
6/30/2021	15	-9	-10	-10	N/A
3/31/2021	14	-7	-8	-8	N/A
12/31/2020	13	-7	-8	-8	N/A
9/30/2020	12	-7	-6	-6	N/A
6/30/2020	12	-6	-6	-5	N/A
3/31/2020	12	-6	-5	-5	N/A
12/31/2019	11	-6	-3	-3	N/A
9/30/2019	10	-5	-3	-3	N/A
6/30/2019	9	-5	N/A	-3	N/A
3/31/2019	8	-6	N/A	-3	N/A
12/31/2018	7	-6	N/A	-5	N/A
9/30/2018	7	-7	N/A	-6	N/A
6/30/2018	7	-7	N/A	-6	N/A
3/31/2018	7	-7	N/A	-7	N/A
12/31/2017	7	-7	N/A	-6	N/A
9/30/2017	7	-7	N/A	-5	N/A
6/30/2017	7	-8	N/A	-5	N/A
3/31/2017	6	-8	N/A	-6	N/A
12/31/2016	6	-8	N/A	-6	N/A
9/30/2016	6	-8	N/A	-6	N/A
6/30/2016	5	-5	N/A	-6	N/A
3/31/2016	5	-7	N/A	-7	N/A
12/31/2015	5	-8	N/A	-9	N/A
9/30/2015	4	-9	N/A	-9	N/A
6/30/2015	3	-13	N/A	-10	N/A
3/31/2015	4	-11	N/A	-9	N/A

애널리스트 향후 성장 전망

수입 대 저축률: CLPT 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: CLPT 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: CLPT 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: CLPT 의 수익(연간 41.5%)이 US 시장(연간 10.5%)보다 빠르게 성장할 것으로 예상됩니다.

고성장 매출: CLPT 의 수익(연간 41.5%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: CLPT의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.

성장 기업 찾아보기

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2026/01/06 04:45
종가	2026/01/06 00:00
수익	2025/09/30
연간 수익	2024/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 Github 페이지에서 확인할 수 있으며, 보고서 활용 방법에 대한 가이드와 Youtube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

ClearPoint Neuro, Inc.는 6명의 분석가가 다루고 있습니다. 이 중 2명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Andrew D'Silva	B. Riley Securities, Inc.
Kyle Bauser	B. Riley Securities, Inc.
Anderson Schock	B. Riley Securities, Inc.

ClearPoint Neuro 향후 성장

Future 기준 점검 2/6

핵심 정보

최근 향후 성장 업데이트

Consensus EPS estimates fall by 22%, revenue upgraded

Price target increased by 8.7% to US$25.00

ClearPoint Neuro, Inc. Provides Revenue Guidance for the Full Year of 2025

Price target increased by 21% to US$15.67

ClearPoint Neuro, Inc. Reaffirms Revenue Guidance for the Full Year of 2024

Price target increased by 18% to US$11.83

Recent updates

New major risk - Revenue and earnings growth

ClearPoint Neuro, Inc. (NasdaqCM:CLPT) completed the acquisition of Irras Holdings Inc.

ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) 39% Cheaper Price Remains In Tune With Revenues

Third quarter 2025 earnings: EPS and revenues miss analyst expectations

New major risk - Revenue and earnings growth

Is ClearPoint Neuro (NASDAQ:CLPT) A Risky Investment?

ClearPoint Neuro: AMT-130 Highlights A Bright Future

Paul Larson to Join Clearpoint Neuro, Inc. as Chief Medical Officer Starting in January 2026

Why Investors Shouldn't Be Surprised By ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) 84% Share Price Surge

New major risk - Share price stability

Second quarter 2025 earnings: EPS misses analyst expectations

ClearPoint Neuro, Inc. to Report Q2, 2025 Results on Aug 12, 2025

Independent Director recently sold US$128k worth of stock

Consensus EPS estimates fall by 22%, revenue upgraded

First quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

ClearPoint Neuro, Inc. has filed a Follow-on Equity Offering in the amount of $3.500004 million.

After Leaping 31% ClearPoint Neuro, Inc. (NASDAQ:CLPT) Shares Are Not Flying Under The Radar

Clinical Laserthermia Systems AB (Publ) Together with Its Partner ClearPoint Neuro, Announces FDA Submission to Expand the Labeling of ClearPoint Prism to Include 1.5 T MRI Guidance

ClearPoint Neuro: Fundamentals Continue To Strengthen

ClearPoint Neuro, Inc. to Report Q1, 2025 Results on May 13, 2025

ClearPoint Neuro, Inc., Annual General Meeting, May 21, 2025

Price target increased by 8.7% to US$25.00

Cell And Gene Therapy Delivery Will Expand Global Partnerships

President exercised options and sold US$345k worth of stock

ClearPoint Neuro, Inc. Provides Revenue Guidance for the Full Year of 2025

Full year 2024 earnings: EPS and revenues miss analyst expectations

After Leaping 25% ClearPoint Neuro, Inc. (NASDAQ:CLPT) Shares Are Not Flying Under The Radar

ClearPoint Neuro, Inc. to Report Q4, 2024 Results on Feb 26, 2025

New minor risk - Share price stability

After Leaping 26% ClearPoint Neuro, Inc. (NASDAQ:CLPT) Shares Are Not Flying Under The Radar

ClearPoint Neuro Announces FDA De Novo Marketing Authorization of SmartFlow Cannula for Direct Delivery of Gene Therapy to the Brain

Price target increased by 21% to US$15.67

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

ClearPoint Neuro, Inc. Reaffirms Revenue Guidance for the Full Year of 2024

ClearPoint Neuro, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Investors Appear Satisfied With ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Prospects As Shares Rocket 28%

Price target increased by 18% to US$11.83

Is ClearPoint Neuro (NASDAQ:CLPT) Weighed On By Its Debt Load?

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

New minor risk - Share price stability

ClearPoint Neuro, Inc. Raises Revenue Guidance for the Year 2024

Insufficient new directors

ClearPoint Neuro, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Investors Appear Satisfied With ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Prospects As Shares Rocket 26%

ClearPoint Neuro, Inc.(NasdaqCM:CLPT) dropped from Russell Small Cap Completeness Index

ClearPoint Neuro, Inc. Initiates Its Full Market Release of the Smartframe

Consensus EPS estimates upgraded to US$0.66 loss

ClearPoint Neuro, Inc. (NASDAQ:CLPT) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

ClearPoint Neuro, Inc. Announces FDA Clearance of Prism Bone Anchor Accessory

ClearPoint Neuro, Inc. Announces Initiation of Limited Market Release for the SmartFrame OR™ Stereotactic System

ClearPoint Neuro: Macro-Induced Multiple Compression

ClearPoint Neuro, Inc. to Report Q1, 2024 Results on May 07, 2024

Are ClearPoint Neuro, Inc. (NASDAQ:CLPT) Investors Paying Above The Intrinsic Value?

ClearPoint Neuro, Inc., Annual General Meeting, May 15, 2024

ClearPoint Neuro, Inc. Reaffirms Revenue Guidance for the Year 2024

Analysts Have Made A Financial Statement On ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Yearly Report

Full year 2023 earnings: EPS and revenues exceed analyst expectations

ClearPoint Neuro, Inc. Announces Preclinical Results of an in Vivo Validation Study Have Been Published in the Journal of Neurosurgery

President exercised options and sold US$69k worth of stock

New minor risk - Shareholder dilution

ClearPoint Neuro, Inc. to Report Q4, 2023 Results on Mar 12, 2024

ClearPoint Neuro, Inc. has completed a Follow-on Equity Offering in the amount of $15.000011 million.

ClearPoint Neuro, Inc. has filed a Follow-on Equity Offering.

ClearPoint Neuro, Inc. Announces FDA Clearance and First-In-Human Cases Performed with the New 2.2 Software Version and the Integrated Maestro Brain Model

Now 21% undervalued

Clearpoint Neuro Receives 510(K) Clearance for Smartframe or Stereotactic System

ClearPoint Neuro, Inc. Provides Revenue Guidance for the Full Year 2024

Should You Investigate ClearPoint Neuro, Inc. (NASDAQ:CLPT) At US$6.18?